Today marks Metastatic Breast Cancer Awareness Day — a day dedicated to honoring those living with advanced breast cancer and the families, researchers, and advocates working tirelessly to improve their care and outcomes. We’re spotlighting an important discussion...
LiveLung will host its monthly patient education webinar, featuring Seema Nagpal, M.D., Neuro-Oncologist at Stanford Health Care, for an in-depth discussion on Leptomeningeal Metastases (LM) — a challenging and often underdiagnosed complication of advanced cancers....
This past weekend, CNSide Diagnostics’ Andrew Sims and Conroy Campbell proudly participated in the Winship 5K in support of the Winship Cancer Institute of Emory University and its mission to advance lifesaving cancer research. Held during Breast Cancer Awareness...
Marc Hedrick, M.D., President and CEO of Plus Therapeutics (Nasdaq: PSTV), recently traveled to the New York Stock Exchange (NYSE) to join Remy Blaire of FINTECH.TV for an in-depth discussion on the company’s National Coverage Agreement with UnitedHealthcare Insurance...
Marc Hedrick, M.D., President and CEO of Plus Therapeutics (Nasdaq: PSTV), recently sat down with Jonathan D. Grinstein, PhD, of Inside Precision Medicine to discuss the company’s exciting news: a National Coverage Agreement with UnitedHealthcare Insurance Company...
CNSide Diagnostics, a leader in precision diagnostics for central nervous system (CNS) cancers, is pleased to announce the addition of Kelly Kreitzburg Ondrasek, PhD, as Medical Science Liaison (MSL). Dr. Kreitzburg Ondrasek brings extensive scientific expertise and a...
Russell Bradley, President and General Manager of CNSide Diagnostics, was recently featured in an interview with InnovationMap, where he discussed the company’s CNSide® Cerebrospinal Fluid (CSF) Assay Platform — an advanced diagnostic designed to help clinicians...
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced today that it has entered into a national agreement with UnitedHealthcare Insurance Company (NYSE: UNH) to provide access to its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory-developed test (LDT)....
CNSide Diagnostics, a leader in precision diagnostics for central nervous system (CNS) cancers, is excited to announce the addition of Elaine Luckey as the company’s new Director of Quality. Elaine brings extensive experience in quality management systems, regulatory...